Thursday, November 29, 2007

Fate Therapeutics Launches Stem Cell Firm

Seattle-based Fate Therapeutics said Thursday afternoon that it has launched a new biotechnology company, which will develop drugs to control cell fate. The firm said it is targeting the use of adult stem cells for healing, using small molecule drugs. The firm said it has received $12M in backing from ARCH Venture Partners, Polaris Venture Partners, Venrock, and OVP. The firm's team includes Randall Moon, the Director of the University of Washington's Institute for Stem Cell and Regenerative Medicine, along with stem cell scientists from Stanford, Scripps Research Institute, and Harvard. More information »